You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma : the V-325 Study Group . PURPOSE For patients with advanced gastric or gastroesophageal cancer ( AGGEC ) providing clinical benefit with improved palliation is highly desirable . However , a prospective evaluation of clinical benefit in AGGEC patients has never before been reported in a phase III setting . PATIENTS AND METHODS In a multinational trial ( V325 ) , 445 patients were randomly assigned and treated with either docetaxel plus cisplatin and fluorouracil ( DCF ) or cisplatin and fluorouracil ( CF ) . Clinical benefit was prospectively evaluated in this trial as a secondary end point . The primary measure for clinical benefit analysis was time to definitive worsening by one or more categories of Karnofsky performance status ( KPS ) . Secondary clinical benefit end points included time to 5 % definitive weight loss , time to definitive worsening of appetite by one grade , pain-free survival ( defined as time to first appearance of pain ) , and time to first cancer pain-related opioid intake . Clinical benefit assessments were recorded at each clinic visit . RESULTS Clinical benefit assessments were performed in more than 75 % of patients throughout V325 . DCF significantly prolonged time to definitive worsening of KPS compared with CF ( median , 6.1 v 4.8 months ; hazard ratio , 1.38 ; 95 % CI , 1.08 to 1.76 ; log-rank P = .009 ) . Although time to definitive weight loss and time to definitive worsening of appetite favored DCF , the results were not statistically significant . Pain-free survival and time to first cancer pain-related opioid intake were comparable . CONCLUSION To our knowledge , V325 is the first phase III trial to report clinical benefit in AGGEC patients . Clinical benefit was assessed beyond protocol-specific chemotherapy . The addition of D to CF not only significantly improved clinical benefit but also improved quality of life , time to progression , and overall survival compared with CF .
{"Intervention": ["fluorouracil ( DCF )", "protocol-specific chemotherapy", "docetaxel plus cisplatin", "D", "fluorouracil", "DCF", "docetaxel plus fluorouracil", "cisplatin", "fluorouracil ( CF )", "CF"], "Outcome": ["time to first appearance of pain", "Karnofsky performance status", "pain-free survival", "time to 5 % definitive weight loss , time to definitive worsening of appetite by one grade ,", "Pain-free survival and time to first cancer pain-related opioid intake", "quality of life", ", time to progression , and", "( defined as", "time to definitive worsening of KPS", ") , and time to first cancer pain-related opioid intake .", "overall survival", "time to definitive weight loss and time to definitive worsening of appetite", "time to definitive worsening"], "Participant": ["445", "advanced gastric or gastroesophageal cancer adenocarcinoma", "advanced gastric or gastroesophageal cancer ( AGGEC )"]}